Discovery of dual-targeted molecules based on Olaparib and Rigosertib for triple-negative breast cancer with wild-type BRCA
- 5 October 2024
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 113, 117936
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
- Natural Science Research of Jiangsu Higher Education Institutions of China
This publication has 39 references indexed in Scilit:
- The treatment landscape of triple-negative breast cancerMedical Oncology, 2024
- Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational statusBreast Cancer, 2024
- Tumor-Infiltrating Lymphocytes in Triple-Negative Breast CancerJAMA, 2024
- Targeting RAS guanyl releasing protein 1 promotes T lymphocytes infiltrations and improves anti‐programmed death receptor ligand 1 therapy response of triple‐negative breast cancerClinical and Translational Medicine, 2023
- Discovery of dual PARP and CDK6 inhibitors for triple-negative breast cancer with wild-type BRCABioorganic Chemistry, 2023
- Identification and evaluation of a novel PARP1 inhibitor for the treatment of triple-negative breast cancerChemico-Biological Interactions, 2023
- Mutational spectrum of BRCA1/2 genes in Moroccan patients with hereditary breast and/or ovarian cancer, and review of BRCA mutations in the MENA regionBreast Cancer Research and Treatment, 2022
- Recent advances in α,β-unsaturated carbonyl compounds as mitochondrial toxinsEuropean Journal of Medicinal Chemistry, 2019
- Chlorambucil-conjugated platinum(IV) prodrugs to treat triple-negative breast cancer in vitro and in vivoEuropean Journal of Medicinal Chemistry, 2018
- Olaparib hydroxamic acid derivatives as dual PARP and HDAC inhibitors for cancer therapyBioorganic & Medicinal Chemistry, 2017